This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Menorrhagia Study in Women With Treatment-resistant Menorrhagia

This study has been completed.
TAP Pharmaceutical Products Inc.
Information provided by:
Bayer Identifier:
First received: February 7, 2006
Last updated: December 29, 2014
Last verified: December 2014
The aim of this study is to explore effects of the investigational product for the treatment of treatment-resistant menorrhagia without organic cause.

Condition Intervention Phase
Menorrhagia Drug: Asoprisnil (BAY86-5294) Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Double-blind, Placebo-controlled, Randomized, Parallel Group Study to Evaluate the Effects of Different Doses of SH T 00127B in Women With Treatment-resistant Menorrhagia Aged 30 to 55 Years After Daily Oral Administration of Multiple Doses for 35 up to 50 Days

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Individual relative change in uterine bleeding scores by PBAC [ Time Frame: Pretreatment cycle treatment phase ]

Secondary Outcome Measures:
  • Endometrial thickness [ Time Frame: End of treatment ]
  • Adverse events collection [ Time Frame: Whole treatment period ]
  • Bleeding pattern [ Time Frame: Treatment period ]
  • Endometrial histology incl. immunohistochemical evaluations [ Time Frame: End of treatment ]

Enrollment: 26
Study Start Date: November 2001
Study Completion Date: January 2004
Arms Assigned Interventions
Experimental: Arm 1 Drug: Asoprisnil (BAY86-5294)
Experimental: Arm 2 Drug: Asoprisnil (BAY86-5294)
Experimental: Arm 3 Drug: Asoprisnil (BAY86-5294)
Placebo Comparator: Arm 4 Drug: Placebo

Detailed Description:
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Ages Eligible for Study:   30 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with treatment-resistant menorrhagia scheduled for hysterectomy.

Exclusion Criteria:

  • Organic causes of menorrhagia
  • Current hormone treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00288691

Sponsors and Collaborators
TAP Pharmaceutical Products Inc.
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Therapeutic Area Head, Bayer Schering Pharma AG Identifier: NCT00288691     History of Changes
Other Study ID Numbers: 90955
Study First Received: February 7, 2006
Last Updated: December 29, 2014

Keywords provided by Bayer:
Treatment-resistant menorrhagia

Additional relevant MeSH terms:
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Menstruation Disturbances
Pathologic Processes processed this record on July 19, 2017